The global non-small cell lung cancer market is anticipated to grow at a CAGR of 9.6% during the forecast period (2021-2027). The market growth is mainly attributed to the increase in air pollution across the globe. Rising pollution due to the number of carbon particles inhaled by humans causes several problems including lung cancer. The risk is sometimes equivalent to breathing second-hand tobacco smoke and comes from sources like industry, power generation, transportation, and domestic burning. Moreover, smoking cigarettes is also estimated to be one of the major causes of lung cancer among people. According to the reports of the American Cancer Society, In the US, 80% of lung cancer deaths are caused by smoking as the changes in the lung tissue begin almost immediately which damages the line of the lungs. Besides, the rising prevalence of cancer is driving the market growth. For instance, according to the International Agency for Research on Cancer, in 2020, there was around 227,875 lung cancer patient in theUS and it is estimated to reach at around 314,015 by 2040.
Browse the full report description of "Global Non-Small Cell Lung Cancer Market Size, Share & Trends Analysis Report By Type (Adenocarcinomas, Squamous Cell Carcinoma, Large Cell Carcinomas, and Others), By Therapy (Chemotherapy, Targeted Therapy, Radiation Therapy, Surgery, Cryosurgery, and Others). By Diagnosis (CT Scan, X-Rays, Sputum Cytology, Bronchoscopy, Laboratory Tests, Thoracoscopy, and Others), By End-User (Multispeciality Hospitals and Cancer Research Centers) Forecast, 2021-2027" at https://www.omrglobal.com/industry-reports/non-small-cell-lung-cancer-market
In addition to this, radiation, exposure to radon gas, certain metals, and some organic chemicals are some of the other factors that lead to lung cancer-causing the growth of the treatment of lung cancer. Government organizations and initiatives also play a major role in the treatment of lung cancer to increase the survival rate. For instance, in May 2020, FDA approved CYRAMZA in combination with erlotinib for the treatment of metastatic non-small cell lung cancer (NSCLC). Moreover, in the same month, FDA also improved Roche’s Tecentriq for adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression. In addition to this, in January 2020, Bristol Myers Squibb received European Commission Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with two cycles of chemotherapy for first-line treatment of metastatic Non-Small Cell Lung Cancer.
Market Coverage
o By Type
o By Therapy
o By Diagnosis
o By End-User
o North America
o Europe
o Asia-Pacific
o Rest of the World
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Non-Small Cell Lung Cancer Market Report Segment
By Type
By Therapy
By Diagnosis
By End-User
Global Non-Small Cell Lung Cancer Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/non-small-cell-lung-cancer-market